Bookmark
Forward
Explore Curated Studies Results
Explore Literature Results
Explore Clinical Trials Results
QuickView for PI-103 (compound)
Most Correlated Studies
- SY5Y cells overexpressing FOXO3A treated with PI-103
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
- L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
- L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Most Relevant Literature
- RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt path…
- Development of a bioavailable boron-containing PI-103 Bioisostere, PI-103BE.
- Two-pore channel blockade by phosphoinositide kinase inhibitors YM201636 and PI-103 determined by a …
- Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivi…
- Synergistic Anticancer Strategy of Sonodynamic Therapy Combined with PI-103 Against Hepatocellular C…
Most Relevant Clinical Trials
- A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders
- Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Perfor…
- Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Typ…
- A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy
- A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing…
